Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-121 triple combination versus elexacaftor/tezacaftor/ivacaftor in cystic fibrosis with F508del/minimal function genotype
MOH_2022-02-01_010579Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing ELX/TEZ/IVA + IVA control arm with VX-121/TEZ/D-IVA experimental arm (2 arms). Started Jan 2022; status: completed.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2022-02-01_010579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-01_010579.